Follow Thermo Fisher to never miss an important update.
The company launched its VaxEvo CD 293 Medium, a specialized liquid used to grow the human cells that produce adenovirus vaccines. By making this medium animal-free and chemically defined, the company helps drugmakers meet strict safety standards while making it easier to scale up from a lab setting to a full factory.
This launch is a classic example of the company's razor-and-blade model. While high-end lab machines get the headlines, the recurring sales of specialized liquids and chemicals needed to run those machines provide a steady, high-margin stream of income that makes the business more predictable.
Source: Business Wire
Thermo Fisher has completed multiple installations of its Optis FIB-SEM, a high-end system that combines ion beams and electron microscopes to analyze semiconductor samples. As chips become smaller and more complex, manufacturers need these tools to find tiny defects and ensure their designs actually work before moving to full production.
While the company is best known for healthcare and lab equipment, its role in the semiconductor supply chain is a key part of its business. These installations show that even as chipmakers face pressure to innovate faster, they are relying on Thermo Fisher's automated tools to handle the precise data needed for next-generation electronics.
Source: Business Wire
Thermo Fisher’s board approved a plan to buy back up to 5 billion dollars of its own stock. This new authorization replaces a previous plan that had about 1 billion dollars left, effectively adding 4 billion dollars to its capacity for repurchases.
A buyback is when a company uses its cash to buy its own shares from the market, which reduces the total number of shares and makes each remaining share own a larger piece of the business. This move signals that management is confident in its cash flow and believes the stock is a good place to put capital to work for owners.
Source: Business Wire
Thermo Fisher launched a new line of chemical mixes, called master mixes, used in quantitative PCR testing. This process is a standard way labs measure and analyze DNA for research and medical diagnostics. These new products are designed to be a cheaper option for laboratories that are trying to manage tight budgets without losing the accuracy of their results. While this is a routine product update, it shows how the company is defending its market share by offering options at different price points as some research customers spend more cautiously.
Source: Business Wire
Argus Research kept its buy rating on the company and set a price target of $780. This is notably higher than the average analyst target of $694 and suggests the firm sees more room for the stock to rise than many of its peers. This follows a recent trend of analysts raising their expectations after the company showed it could grow earnings even while some customers were spending less. While a single target change is routine, it reflects growing confidence in the company's ability to gain market share as a one-stop shop for lab equipment.
Source: Argus Research
Management consistently sets a predictable bar and clears it with precision, delivering eight straight quarters of beats even as lab spending fluctuated globally.
| Expectation | |
|---|---|
| EPS | $7.12 |
| Revenue | $12.84B |
Follow Thermo Fisher to get the latest and most important updates.
Follow TMO